Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2000, p. 3200-3204, Vol. 38, No. 9
Public Health Research Institute Tuberculosis
Center1 and Department of Microbiology,
New York University School of Medicine,2 New
York, New York 10016, and Wadsworth Center, New York State
Department of Health, Albany, New York 12201-20023
Received 22 December 1999/Returned for modification 23 February
2000/Accepted 16 May 2000
The Mycobacterium tuberculosis strains H37Rv and H37Ra
are the most commonly used controls for M. tuberculosis identification in the clinical and research
laboratory setting. To reduce the likelihood of misidentification and
possible cross-contamination with this laboratory neotype, it is
important to be able to distinguish H37 from clinical isolates. To
provide a reference for identifying H37, we used multiple molecular
techniques to characterize H37 strains, including 18 of the most
frequently used variants available through the American Type Culture
Collection. Isolates were genotyped using gene probes to
IS6110 and IS1085. In addition, we performed polymorphic GC-rich sequence typing (PGRS), spoligotyping,
determination of variable number of tandem repeats (VNTR), and PCR
amplification of the mtp40, msx4, and
mpp8 polymorphic regions. Southern hybridization with
IS6110 provided the most discrimination, differentiating the 18 H37 isolates into 10 discrete patterns made up of 9 H37Rv variants and 1 H37Ra variant. PGRS, IS1085,
mpp8, and spoligotyping were not able to distinguish any
H37 variants, while VNTR and msx4 discriminated two. Only
IS6110 and spoligotyping could distinguish the H37 strain
from clinical isolates. In summary, spoligotyping and
IS6110 provide a rapid and accurate way to identify H37
contamination, though IS6110 can, in addition, classify
many of the H37 variants that would otherwise require phenotypic segregation.
The genotyping of
Mycobacterium tuberculosis, primarily for outbreak
identification, has become a model for the application of strain typing
in the field of molecular epidemiology. In the clinical
mycobacteriology laboratory, strain typing has been essential in the
identification of laboratory cross-contamination (1, 2, 5, 16,
25), an almost impossible task prior to the inception of
molecular techniques. The source of laboratory cross-contamination can
be a clinical sample (3, 15, 16) or often the M. tuberculosis control strain maintained by the clinical
mycobacteriology laboratory (12, 13). In this regard, the
virulent and attenuated H37 variants are the most commonly used control
isolates and thus are a major source of false-positive results in
M. tuberculosis identification as well as
cross-contamination (13). The purpose of this study is to
provide the mycobacteriologist with a molecular guide for
discriminating H37 from clinical isolates in the genotyping laboratory.
The strain H37 was originally isolated in 1905 and gained attention for
its noted virulence in the guinea pig model, a distinctive characteristic used in the classification of "human tuberculosis" in the early 1900s. In 1934, H37 was dissociated into "virulent" (Rv) and "avirulent" (Ra) strains (18, 24). The
original 1905 H37 isolate was then discontinued, and the
H37Rv and H37Ra isolates have been maintained at the Trudeau
Institute ever since. Several drug-resistant derivatives have
been generated during the years, accounting in part for the 18 H37 variants available through the Trudeau Mycobacterial
Collection (TMC) and the American Type Culture Collection
(ATCC). Hence, there are 15 H37Rv and 3 H37Ra progenies maintained at the Trudeau Institute and the ATCC.
Although H37 variants are widely used as reference strains in
mycobacteriology and molecular biology laboratories, their
IS6110 patterns are often mistaken for clinical isolates
displaying similar fingerprint patterns (unpublished data). In this
respect, it is essential for both patient care and tuberculosis control
to be able to properly recognize and genotype all possible H37
variants. To do so, we have employed several of the most common
M. tuberculosis typing techniques in order to characterize
the 18 H37 variants available through the ATCC. The results indicate
that both spoligotyping and IS6110 provide a rapid means of
distinguishing H37 strains from clinical isolates. In addition,
IS6110 DNA fingerprinting analysis further discriminates the
collection into 10 distinct H37 variants.
M. tuberculosis reference strains.
The 18 different catalogued H37 variants were purchased from the ATCC. The
strains were deposited at the ATCC as follows: 25177 (C. L. Larson, University of Montana, lot 1-23-69), 35618 (A. G. Karlson,
Mayo Clinic, lot 1-21-70), and 27294 (G. P. Kubica, Trudeau
Laboratories, lot 1-27-72). All other strains (35820, 35821, 35822, 35823, 35824, 35825, 35826, 35827, 35828, 35829, 35830, 35835, 35836, 35837 and 35838) were deposited by the Trudeau Institute in lot 2-01-85 (data were kindly provided by the ATCC). In addition, the primary
collection of H37 variants was also received, as a kind gift of R. North, from the TMC, Trudeau Institute, Saranac Lake, N.Y. TMC and ATCC
reference numbers and susceptibility data are shown in Table
1.
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Molecular Characterization of Mycobacterium
tuberculosis H37Rv/Ra Variants: Distinguishing the Mycobacterial
Laboratory Strain
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
H37Rv and H37Ra collectiona
M. tuberculosis clinical isolates. A search of the IS6110 fingerprint database maintained at the Public Health Research Institute Tuberculosis Center (TB Center) (n = 11,000) identified 131 H37Rv and H37Ra isolates which matched at least one of the nine H37Rv and one H37Ra patterns reported in this study. The fingerprint search was conducted using each of the 10 possible H37Rv and H37Ra patterns as a prototype. The TB Center database includes approximately 8,600 isolates from New York City and New Jersey, while the remaining samples are from seven additional states in the United States and from the former USSR, Singapore, South Africa, Romania, Egypt, Israel, Venezuela, Honduras, Mexico, India, Chile, the Czech Republic, and Kenya.
Genotyping by IS6110. Chromosomal DNA extraction and strain typing by IS6110 was performed according to the standard method using the right-side hybridization probe (IS6110-3'-probe) (27). The same membrane was rehybridized with the left-side IS6110 probe (IS6110-5'-probe), the direct repeat (DR) probe, and the insertion sequence IS1085.
Genotyping by using PGRS probe. Chromosomal DNA was restricted with AluI and hybridized with the polymorphic GC-rich repetitive sequence (PGRS) probe (GenBank accession no. M95490) (14). All other electrophoretic and hybridization conditions were the same as for IS6110 genotyping (26).
Spoligotyping. The DR of the extracted M. tuberculosis DNA was amplified by PCR and analyzed according to the spoligotyping protocol as described by Kamerbeek and colleagues (8). The AluI-digested DNA membranes generated for PGRS typing were also probed with the DR probe to confirm spoligotyping results (27).
Determination of VNTR. The variable number of tandem repeat (VNTR) loci ETR-A to ETR-E were determined as described by Frothingham and Meeker-O'Connell (7). Briefly, the five selected loci were amplified by PCR and analyzed on a 2% agarose gel.
PCR amplification of the polymorphic fragments msx4, mpp8, and mtp40. Amplicons to segments msx4, mpp8, and mtp40 were generated and compared from all 18 H37 variants. The polymorphic segments msx4 and mpp8 containing two DR sequences were PCR amplified with primer pairs SX1-SX2 and PP3-PP4, respectively, as described by Namwat et al. (11). PCR amplification of the mtp40 fragment was accomplished using primers PT1 and PT2 (6).
Computer analysis of fingerprint patterns. The IS6110 hybridization patterns were electronically digitized and compared with a pattern-matching computer program on a Sun Sparc5 workstation using a Bioimage Whole Band Analyzer (software version 3.4; Genomic Solutions, Ann Arbor, Mich.). The Jaccard matching method and unweighted-pair-group method using arithmetic averages (UPGMA)-average linkage clustering was used to identify related patterns, in accord with the protocol of the Centers for Disease Control and Prevention, The National Tuberculosis Genotyping and Surveillance Network.
| |
RESULTS |
|---|
|
|
|---|
Eighteen H37 variants available through the ATCC and their
respective parent strains from the Trudeau Institute were typed by the
now standard IS6110 Southern blot hybridization analysis (26). A total of 10 distinct fingerprint patterns were
identified (Fig. 1). The nine
patterns associated with the H37Rv strains were assigned the
genotypes Rv1 through Rv9 and all three
H37Ra strains (35835, 35836, and 25177) shared the same
Ra1 fingerprint pattern (Table 1). The Rv variants
were Rv1 (strain 35820), Rv2 (strain
35821), Rv3 (strain 35823), Rv4 (strain
35829), Rv5 (strain 35824), Rv6 (strain
35825), Rv7 (strains 35837, 35838, and 27294), Rv8 (strains 35822, 35826, 35827, 35828, and 35830), and
Rv9 (strain 35618). The number of IS6110
hybridizing bands ranged from 14 (Rv4) to 16 (Rv7) bands for H37Rv and was 16 bands for H37Ra
(Ra1; Fig. 1).
|
The spoligopattern of H37 variants was unique (spoligotype S00001; Fig.
2). The S00001 spoligopattern has only
been observed in isolates of H37 variants and clinical samples
determined to have been cross-contaminated by H37 strains. VNTR
patterns were determined by analysis of the products of the PCR
amplification of the five chromosomal loci ETR-A to ETR-E. All 18 ATCC isolates displayed the same VNTR pattern (33433), except for
Rv5. PGRS-typing, spoligotyping, and VNTR analysis did not
differentiate the 18 H37 variants within the TMC and ATCC isolates (see
Fig. 4).
|
PCR amplification of three other polymorphic regions, the two repetitive sequences msx4, mpp8, and mtp40, and hybridization with IS1085, could not be used to distinguish H37 variants from other genetically unrelated M. tuberculosis strains. The msx4 PCR products of all H37 variants were shown to be 437 bp in length, with the exception of strain ATCC 35825, which generated a 720-bp amplicon (data not shown).
Genotyping clinical isolates. Searching the IS6110 DNA fingerprint pattern database at the TB Center (n = ~11,000) using Rv1 to Rv9 and Ra1 as prototypes, identified 131 IS6110 patterns that matched exactly at least 1 of the 18 H37 variants. A total of 102 samples matched H37Ra type Ra1, 27 matched H37Rv type Rv7, and 1 each matched Rv1 and Rv8. Of these, 45 samples identified as H37Ra were previously reported as known cases of cross-contamination following an investigation by the New York City Department of Health (13). Three H37Ra samples were from outside the United States. The New York State Department of Health confirmed an additional 14 H37Ra strains to be cases of laboratory cross-contamination (12). Of the remaining 69 cases, 37 were confirmed to be contamination by the source laboratories, and the remaining are being investigated by the responsible entities.
Five additional samples had a similar but not exact match with one of the H37Rv or H37Ra variants. The five samples differed from Rv1 to Rv9 and Ra1 by one or two hybridizing bands according to IS6110 analysis (Fig. 3). These samples were designated Rv10 and Rv11 and Ra2 through Ra4 (Fig. 3). Further analysis of all five isolates by the IS1085, VNTR, PGRS, and spoligotype methods failed to distinguish these samples from the reference TMC-ATCC prototypes (Fig. 4). The PGRS profile of H37 Rv1, Rv7, Rv8, Rv10 and Rv11, and Ra1 and Ra4 can be seen in Fig. 4.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In the speciation and susceptibility testing of M. tuberculosis in the clinical laboratory, suspicion of contamination is heightened by the finding of an unusually high number of positive cultures per time period and by inconsistencies between the patient's clinical presentation and his or her laboratory results (10). Suggested cases of contamination are forwarded to a limited number of genotyping laboratories to perform molecular analysis to confirm or reject the possibility of contamination, primarily on a case-by-case basis (1, 2, 5, 16, 25). Often, genotyping and mycobacteriology laboratories are unaware of which H37 variant they are employing as controls, confounding the identification of contaminants. In this study, we have provided a collection of patterns for H37 and its variants for use as a reference by genotyping laboratories.
Genotyping analysis of H37 variants.
All 18 ATCC H37 variants
had the same spoligotype pattern, designated S00001. Although
spoligotype pattern S00001 did not discriminate one ATCC H37 variant
from another, it proved definitive in distinguishing the ATCC H37
collection from all other clinical isolates analyzed by this technique
(n
2,400).
Identifying H37 cross-contamination among clinical isolates. The ability to discriminate between the H37 variants and real clinical samples has important public health implications. In this study, the IS6110 fingerprint patterns of 131 clinical isolates, most of which were confirmed contaminants, matched that of one of the reference H37 strains. Random spoligotyping, PGRS, and VNTR analyses confirmed the relatedness of these 131 isolates to the reference ATCC H37 variants.
In addition, two H37Rv and three H37Ra IS6110 patterns (Rv10 and Rv11 and Ra2 to Ra4), which are distinct from but related to the ATCC collection, were identified among clinical specimens from our database of 11,000 fingerprints. These five isolates, also confirmed cases of laboratory contamination, were found to have the same spoligotype, PGRS, and VNTR as the TMC-ATCC isolates, and we infer that the isolates have evolved in the clinical laboratory from one of the reference strains. However, investigators should be aware that, given the origins of H37, it is possible that "true" clinical isolates exist with an identical spoligotype and similar IS6110 pattern as the reference strain H37. Thus, while genotyping may be used to initiate or direct investigation, clinical decisions regarding contamination should be based on a combination of molecular and medical information. Taken together, analysis of our clinical M. tuberculosis collection as well as ATCC isolates indicates that a combination of spoligotyping and IS6110 fingerprinting has proven to be a reliable tool in the proper identification of H37 cross-contamination. Unlike PGRS analysis, the H37 spoligopatterns (S00001) were unambiguous, making interpretation consistent. IS6110 fingerprinting should be used to confirm the proper identification of an H37 isolate.| |
ACKNOWLEDGMENTS |
|---|
This research was supported in part by the Centers for Disease Control and Prevention, National Tuberculosis Genotyping and Surveillance Network cooperative agreement.
We are grateful to R. North for providing us with the H37 variants from the TMC. We thank W. Eisner and H. Marasco for assistance in preparing the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Public Health Research Institute Tuberculosis Center, 455 First Ave., New York, NY 10016. Phone: (212) 578-0850. Fax: (212) 578-0853. E-mail: barry{at}phri.nyu.edu.
Publication 72 from the Public Health Research Institute
Tuberculosis Center.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bauer, J., V. O. Thomsen, S. Poulsen, and A. B. Andersen. 1997. False-positive results from cultures of Mycobacterium tuberculosis due to laboratory cross-contamination confirmed by restriction fragment length polymorphism. J. Clin. Microbiol. 35:988-991[Abstract]. |
| 2. | Bhattacharya, M., S. Dietrich, L. Mosher, F. Siddiqui, B. E. Reisberg, W. S. Paul, and J. R. Warren. 1998. Cross-contamination of specimens with Mycobacterium tuberculosis: clinical significance, causes, and prevention. Am. J. Clin. Pathol. 109:324-330[Medline]. |
| 3. | Braden, C. R., G. L. Templeton, W. W. Stead, J. H. Bates, M. D. Cave, and S. E. Valway. 1997. Retrospective detection of laboratory cross-contamination of Mycobacterium tuberculosis cultures with use of DNA fingerprint analysis. Clin. Infect. Dis. 24:35-40[Medline]. |
| 4. |
Brosch, R.,
W. J. Philipp,
E. Stavropoulos,
M. J. Colston,
S. T. Cole, and S. V. Gordon.
1999.
Genomic analysis reveals variation between Mycobacterium tuberculosis H37Rv and the attenuated M. tuberculosis H37Ra strain.
Infect. Immun.
67:5768-5774 |
| 5. |
De, C. R. M.,
H. Soini,
G. C. Roscanni,
M. Jaques,
M. C. Villares, and J. M. Musser.
1999.
Extensive cross-contamination of specimens with Mycobacterium tuberculosis in a reference laboratory.
J. Clin. Microbiol.
37:916-919 |
| 6. |
Del Portillo, P.,
L. A. Murillo, and M. E. Patarroyo.
1991.
Amplification of a species-specific DNA fragment of Mycobacterium tuberculosis and its possible use in diagnosis.
J. Clin. Microbiol.
29:2163-2168 |
| 7. | Frothingham, R., and W. A. Meeker-O'Connell. 1998. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 144(Pt. 5):1189-1196[Abstract]. |
| 8. | Kamerbeek, J., L. Schouls, A. Kolk, M. van Agterveld, D. van Soolingen, S. Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. van Embden. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914[Abstract]. |
| 9. | Lari, N., L. Rindi, C. Lami, and C. Garzelli. 1999. IS6110-based restriction fragment length polymorphism (RFLP) analysis of Mycobacterium tuberculosis H37Rv and H37Ra. Microb. Pathog. 26:281-286[CrossRef][Medline]. |
| 10. |
MacGregor, R. R.,
L. W. Clark, and F. Bass.
1975.
The significance of isolating low numbers of Mycobacterium tuberculosis in culture of sputum specimens.
Chest
68:518-523 |
| 11. | Namwat, W., P. Luangsuk, and P. Palittapongarnpim. 1998. The genetic diversity of Mycobacterium tuberculosis strains in Thailand studied by amplification of DNA segments containing direct repetitive sequences. Int. J. Tuberc. Lung Dis. 2:153-159[Medline]. |
| 12. | Nivin, B., J. Driscoll, T. Glaser, P. Bifani, and S. Munsiff. Use of spoligotype analysis to detect laboratory cross-contamination. Infect. Control Hosp. Epidemiol., in press. |
| 13. | Nivin, B., P. I. Fujiwara, J. Hannifin, and B. N. Kreiswirth. 1998. Cross-contamination with Mycobacterium tuberculosis: an epidemiological and laboratory investigation. Infect. Control Hosp. Epidemiol. 19:500-503[Medline]. |
| 14. | Palittapongarnpim, P., P. Luangsook, S. Tansuphaswadikul, C. Chuchottaworn, R. Prachaktam, and B. Sathapatayavongs. 1997. Restriction fragment length polymorphism study of Mycobacterium tuberculosis in Thailand using IS6110 as probe. Int. J. Tuberc. Lung Dis. 1:370-376[Medline]. |
| 15. | Segal-Maurer, S., B. N. Kreiswirth, J. M. Burns, S. Lavie, M. Lim, C. Urban, and J. J. Rahal, Jr. 1998. Mycobacterium tuberculosis specimen contamination revisited: the role of laboratory environmental control in a pseudo-outbreak. Infect. Control Hosp. Epidemiol. 19:101-105[Medline]. |
| 16. |
Small, P. M.,
N. B. McClenny,
S. P. Singh,
G. K. Schoolnik,
L. S. Tompkins, and P. A. Mickelsen.
1993.
Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures.
J. Clin. Microbiol.
31:1677-1682 |
| 17. | Steenken, W., and V. Montalbine. 1959. The antituberculous activity of thiomide in vitro and in the experimental animal (mouse and guinea pig). Am. Rev. Respir. Dis. 81:761-763. |
| 18. | Steenken, W., W. H. Oatway, and S. A. Petroff. 1934. Biological studies of the tubercle bacillus. J. Exp. Med. 60:515-543[Abstract]. |
| 19. | Steenken, W., and E. Wolinsky. 1956. Cycloserine: antituberculous activity in vitro and in the experimental animal. Am. Rev. Tuberc. 73:539-546[Medline]. |
| 20. | Steenken, W., and E. Wolinsky. 1950. Effect of antimicrobial agents on the tubercle bacillus and on experimental tuberculosis. Am. J. Med. 9:633-653[CrossRef][Medline]. |
| 21. | Steenken, W., and E. Wolinsky. 1948. Streptomycin in experimental tuberculosis. Am. Rev. Tuberc. 58:353-362. |
| 22. | Steenken, W., E. Wolinsky, M. M. Smith, and V. Montalbine. 1957. Further observations on pyrazinamide alone and in combination with other drugs in experimental tuberculosis. Am. Rev. Tuberc. 76:643-659[Medline]. |
| 23. | Steenken, W., E. Wolinsky, and J. R. Thurston. 1959. The antituberculous activity of kanamycin in vitro and in the experimental animal (guinea pig). Am. Rev. Tuberc. 79:66-71[Medline]. |
| 24. | Steenken, W. J., and L. U. Gardner. 1946. History of H37 strain of tubercle bacillus. Am. Rev. Tuberc. 54:62-66. |
| 25. | Van Duin, J. M., J. E. Pijnenburg, C. M. van Rijswoud, P. E. de Haas, W. D. Hendriks, and D. van Soolingen. 1998. Investigation of cross contamination in a Mycobacterium tuberculosis laboratory using IS6110 DNA fingerprinting. Int. J. Tuberc. Lung Dis. 2:425-429[Medline]. |
| 26. |
van Embden, J. D. A.,
M. D. Cave,
J. T. Crawford,
J. W. Dale,
K. D. Eisenach,
B. Gicquel,
P. Hermans,
C. Martin,
R. McAdam,
T. M. Shinnick, and P. M. Small.
1993.
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.
J. Clin. Microbiol.
31:406-409 |
| 27. |
van Soolingen, D.,
P. E. de Haas,
P. W. Hermans,
P. M. Groenen, and J. D. van Embden.
1993.
Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis.
J. Clin. Microbiol.
31:1987-1995 |
| 28. | Weil, A., B. B. Plikaytis, W. R. Butler, C. L. Woodley, and T. M. Shinnick. 1996. The mtp40 gene is not present in all strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 34:2309-2311[Abstract]. |
| 29. | Wolinsky, E., and W. Steenken. 1956. Antituberculous activity of hinconstarch, a synthetic polymer of isoniazid, amithiozone, and starch. Am. Rev. Tuberc. 73:7-8. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|